Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 08, 2016 08:00 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical, Inc. Announces Pricing of $7.75 Million Public Offering of Common Stock and Warrants

NEW YORK, Dec. 08, 2016 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that it has priced a registered public offering...
December 07, 2016 16:07 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical Announces Proposed Public Offering of Common Stock and Warrants

NEW YORK, Dec. 07, 2016 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that it intends to offer and sell, subject to...
October 11, 2016 08:00 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical to Present at 2016 Ophthalmology Innovation Summit on October 13

NEW YORK, Oct. 11, 2016 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that the company has been selected to present...
August 09, 2016 16:01 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical Reports Third Quarter 2016 Financial and Business Results

NEW YORK, Aug. 09, 2016 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today reported results for its third quarter ended June 30,...
August 02, 2016 08:00 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical to Announce Third Quarter 2016 Financial Results on August 9

NEW YORK, Aug. 02, 2016 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that it will report financial results for the...
May 10, 2016 16:01 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical Reports Second Quarter 2016 Financial and Business Results

NEW YORK, May 10, 2016 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today reported results for its second quarter ended March 31,...
May 02, 2016 08:00 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical Announces Appointment of David Brown, MD as Chair of Phase 3 Clinical Program Steering Committee

NEW YORK, May 02, 2016 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that David M. Brown, MD, Clinical Professor of...
April 27, 2016 08:00 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical Announces Presentations at the 2016 Association for Research in Vision and Ophthalmology (ARVO) Conference in Seattle, WA

NEW YORK, April 27, 2016 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced the details of two poster presentations at...
April 26, 2016 08:00 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical to Announce Second Quarter 2016 Financial Results on May 10

NEW YORK, April 26, 2016 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that it will report financial results for...
April 18, 2016 08:00 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical, Inc. Announces Enrollment of First Patient in Phase III Wet AMD Clinical Program

NEW YORK, April 18, 2016 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (NASDAQ:OHRP), a clinical-stage biotechnology company developing novel therapies for ophthalmic diseases, today announced that...